-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Contrasting JATT Acquisition (NYSE:JATT) and Novavax (NASDAQ:NVAX)
Contrasting JATT Acquisition (NYSE:JATT) and Novavax (NASDAQ:NVAX)
Novavax (NASDAQ:NVAX – Get Rating) and JATT Acquisition (NYSE:JATT – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
Profitability
This table compares Novavax and JATT Acquisition's net margins, return on equity and return on assets.
Get Novavax alerts:Net Margins | Return on Equity | Return on Assets | |
Novavax | -114.32% | -572.54% | -55.69% |
JATT Acquisition | N/A | -105.35% | 6.64% |
Insider & Institutional Ownership
42.6% of Novavax shares are held by institutional investors. Comparatively, 44.8% of JATT Acquisition shares are held by institutional investors. 2.1% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Novavax and JATT Acquisition's top-line revenue, earnings per share (EPS) and valuation.Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Novavax | $1.15 billion | 1.46 | -$1.74 billion | ($19.46) | -1.10 |
JATT Acquisition | N/A | N/A | $6.85 million | N/A | N/A |
JATT Acquisition has lower revenue, but higher earnings than Novavax.
Analyst Ratings
This is a breakdown of recent recommendations for Novavax and JATT Acquisition, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Novavax | 2 | 0 | 5 | 0 | 2.43 |
JATT Acquisition | 0 | 0 | 0 | 0 | N/A |
Novavax currently has a consensus price target of $128.25, indicating a potential upside of 497.07%. Given Novavax's higher possible upside, equities research analysts clearly believe Novavax is more favorable than JATT Acquisition.
Summary
JATT Acquisition beats Novavax on 5 of the 9 factors compared between the two stocks.
About Novavax
(Get Rating)
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
About JATT Acquisition
(Get Rating)
JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
Novavax (NASDAQ:NVAX – Get Rating) and JATT Acquisition (NYSE:JATT – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
诺华(纳斯达克:NVAX-GET评级)和JATT收购(纽约证券交易所:JATT-GET评级)都是小盘医疗公司,但哪种投资更好?我们将根据这两家公司的收益、机构所有权、估值、盈利能力、风险、分析师建议和股息的实力进行比较。
Profitability
盈利能力
This table compares Novavax and JATT Acquisition's net margins, return on equity and return on assets.
此表比较了Novavax和JATT收购的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Novavax | -114.32% | -572.54% | -55.69% |
JATT Acquisition | N/A | -105.35% | 6.64% |
净利润率 | 股本回报率 | 资产回报率 | |
诺华 | -114.32% | -572.54% | -55.69% |
JATT收购 | 不适用 | -105.35% | 6.64% |
Insider & Institutional Ownership
内部人与机构所有权
42.6% of Novavax shares are held by institutional investors. Comparatively, 44.8% of JATT Acquisition shares are held by institutional investors. 2.1% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Novavax 42.6%的股份由机构投资者持有。相比之下,JATT收购股份的44.8%由机构投资者持有。Novavax 2.1%的股份由公司内部人士持有。强大的机构持股表明,大型基金管理公司、对冲基金和捐赠基金相信,一只股票有望实现长期增长。
Valuation & Earnings
估值与收益
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Novavax | $1.15 billion | 1.46 | -$1.74 billion | ($19.46) | -1.10 |
JATT Acquisition | N/A | N/A | $6.85 million | N/A | N/A |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
诺华 | 11.5亿美元 | 1.46 | -17.4亿美元 | ($19.46) | -1.10 |
JATT收购 | 不适用 | 不适用 | 685万美元 | 不适用 | 不适用 |
JATT Acquisition has lower revenue, but higher earnings than Novavax.
Jatt收购的收入低于Novavax,但收益高于Novavax。
Analyst Ratings
分析师评级
This is a breakdown of recent recommendations for Novavax and JATT Acquisition, as provided by MarketBeat.
这是MarketBeat提供的最近对Novavax和JATT收购建议的细分。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Novavax | 2 | 0 | 5 | 0 | 2.43 |
JATT Acquisition | 0 | 0 | 0 | 0 | N/A |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
诺华 | 2 | 0 | 5 | 0 | 2.43 |
JATT收购 | 0 | 0 | 0 | 0 | 不适用 |
Novavax currently has a consensus price target of $128.25, indicating a potential upside of 497.07%. Given Novavax's higher possible upside, equities research analysts clearly believe Novavax is more favorable than JATT Acquisition.
诺华目前的一致目标价为128.25美元,表明潜在涨幅为497.07%。考虑到Novavax更有可能的上行空间,股票研究分析师显然认为Novavax比JATT的收购更有利。
Summary
摘要
JATT Acquisition beats Novavax on 5 of the 9 factors compared between the two stocks.
Jatt收购在两只股票之间的9个因素中有5个击败了Novavax。
About Novavax
关于Novavax
(Get Rating)
(获取评级)
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax,Inc.是一家生物技术公司,专注于疫苗的发现、开发和商业化,以预防严重的传染病和满足卫生需求。该公司的候选疫苗包括冠状病毒候选疫苗NVX-CoV2373,它正在进行两项第三阶段试验、一项IIb阶段试验和一项I/II阶段试验;NanoFlu,一种处于第三阶段临床试验的季节性四价流感疫苗候选产品;以及ResVax,一种呼吸道合胞病毒(RSV)融合(F)蛋白质纳米颗粒疫苗候选产品。它还在开发针对老年人(60岁及以上)的第二阶段临床试验的RSV F疫苗,以及针对儿科的第一阶段临床试验。它与武田药品株式会社就新冠肺炎候选疫苗NVX-CoV2373的开发、制造和商业化达成了一项合作协议。Novavax公司成立于1987年,总部设在马里兰州盖瑟斯堡。
About JATT Acquisition
关于JATT收购
(Get Rating)
(获取评级)
JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.
Jatt Acquisition Corp没有重大业务。拟与一个或者多个企业或者实体进行合并、股本置换、资产收购、股份购买、重组或者类似的业务合并。该公司打算专注于主要在生命科学领域运营的业务。Jatt收购公司成立于2021年,总部设在开曼群岛的大开曼群岛。
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
接受Novavax Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Novavax和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧